HIV Drugs Market Share, Growth, Opportunities and Scope 2022-2032

HIV Drugs Market Size- By Drug Class, By Administration, By Distribution Channel- Regional Outlook, Competitive Strategies and Segment Forecasts to 2032

HIV Drugs Market Size- By Drug Class, By Administration, By Distribution Channel- Regional Outlook, Competitive Strategies and Segment Forecasts to 2032

Published: Dec 2022 Report ID: PHAR2213 Pages: 1 - 232 Formats*:     
Category : Pharmaceutical
Global HIV Drugs Market Overview:

According to SPER Market Research, the Global HIV Drugs Market is estimated to reach USD 49.74 million by 2032 with a CAGR of 4.05%. 

The chronic and potentially fatal human immunodeficiency virus (HIV) can be spread to humans to another through sexual contact and blood-to-blood contact. It is a virus that targets CD-4 cells, which are immunological cells, rendering the body more vulnerable to infections and other disorders. The demand for HIV medications has benefited from the increasing incidence of HIV illness throughout time. HIV medications assist in inhibiting HIV replication, hence lowering the risk of transmission. The increase in HIV prevalence and its diagnosis is one of the key reasons driving the growth of the worldwide market for HIV medications. In addition, a growth in the number of government activities aimed at raising public knowledge of causes, symptoms, and treatments has an impact on the market. The availability of generic medications, which are as effective and chemically equivalent to branded medications, is another factor influencing the demand for HIV medications.



Impact of COVID-19 on the Global HIV Drugs Market  
Global healthcare goods import, and export have been hampered by the COVID-19 epidemic. Because of the disruption and volatility in the medicine supply, the pandemic has had a negative effect on the growth of this industry. Additionally, the demand for antiretroviral and antibiotic drugs has decreased internationally due to the decline in the number of new patient prescriptions in the United States, Europe, and other COVID-affected areas and nations. The majority of businesses have seen a negative effect of the epidemic on the sales of HIV/AIDS medications.



Scope of the Report:
 Report Metric Details
 Market size available for years 2019-2032
 Base year considered 2021
 Forecast period 2022-2032
 Segments coveredBy Drug Class, By Administration, By Distribution Channel
 Regions coveredNorth America, Europe, Asia Pacific, Latin America, Middle East and Africa
 Companies CoveredAbbvie Inc., Aelix Therapeutics, AIM ImmunoTech, BioNTech, Biosantech, Boehringer Ingelheim International GmbH, Bristrol-Myers Squibb Company, CytoDyn, Dewpoint Therapeutics, Gilead Sciences, GlaxoSmithKline, ImmunityBio, Janssen Pharmaceuticals, Japan Tobacco, Merck, Mylan, Roche, Shionogi, Starpharma, TaiMed Biologics, Theratechnologies, ViiV Healthcare.
Global HIV Drugs Market Segmentation:

By Drug Class: Based on the Drug Class, Global HIV Drugs Market is segmented as; Chemokine Receptor Inhibitors, Entry Inhibitors – CCR5 Co-Receptor Antagonist, Fusion Inhibitors, Integrate Inhibitors, HIV Integrase Strand Transfer Inhibitors, Multi-Class Combination Products, Protease Inhibitors, Non- Nucleoside Reverse Transcriptase Inhibitors (NNRT’s), Nucleoside Reverse Transcriptase Inhibitors (NRT’s).

By Administration: Based on the Administration, Global HIV Drugs Market is segmented as; Oral, Parenteral.

By Distribution Channel: 
Based on the Distribution Channel, Global HIV Drugs Market is segmented as; Hospital Pharmacies, Online Pharmacies, Retail Pharmacies, Others.

By Region: The worldwide market may be divided into three regions based on geography: North America, Europe, and the rest of the world. It is expected that North America would predominate. The rising incidence of HIV infection among Americans is to blame for this region's dominance. The demand for HIV medications is greatly increased by a large patient base. The population's awareness is another element influencing the progress of the region. Additionally, the existence of major companies that provide cutting-edge HIV medications for the treatment of HIV infection will further accelerate market expansion. Rapid increase in the number of HIV infections and the abundance of HIV medicine manufacturers in this area, Europe is anticipated to be the second-largest market throughout the projection period.

1. Introduction
1.1. Scope of the report
1.2. Market segment analysis

2. Research Methodology
2.1 Research data source
2.1.1 Secondary data
2.1.2 Primary data
2.1.3 SPER’s internal database
2.1.4 Premium insight from KOL’s
2.2 Market size estimation
2.2.1 Top-down and Bottom-up approach
2.3 Data triangulation

3. Executive Summary

4. Market Dynamics
4.1. Driver, Restraint, Opportunity and Challenges analysis
4.1.1 Drivers
4.1.2 Restraints
4.1.3 Opportunities
4.1.4 Challenges 
4.2. COVID-19 Impacts of the Global HIV Drugs Market

5. Market variables and outlook
5.1. SWOT analysis 
5.1.1 Strengths 
5.1.2 Weaknesses 
5.1.3 Opportunities
5.1.4 Threats
5.2. PESTEL analysis 
5.2.1 Political landscape
5.2.2 Economic landscape
5.2.3 Social landscape 
5.2.4 Technological landscape 
5.2.5 Environmental landscape 
5.2.6 Legal landscape 
5.3. PORTER’S five forces analysis 
5.3.1 Bargaining power of suppliers 
5.3.2 Bargaining power of Buyers 
5.3.3 Threat of Substitute 
5.3.4 Threat of new entrant 
5.3.5 Competitive rivalry
5.4. Heat map analysis

6. Global HIV Drugs Market, By Drug Class, 2019-2032 (USD Million)
6.1.  Chemokine Receptor Inhibitors
6.2.  Entry Inhibitors – CCR5 Co-Receptor Antagonist
6.3.  Fusion Inhibitors
6.4.  Integrate Inhibitors, HIV Integrase Strand Transfer Inhibitors
6.5.  Multi-Class Combination Products, Protease Inhibitors
6.6.  Non- Nucleoside Reverse Transcriptase Inhibitors (NNRT’s)
6.7.  Nucleoside Reverse Transcriptase Inhibitors (NRT’s)

7. Global HIV Drugs Market, By Administration, 2019-2032 (USD Million)
7.1. Oral 
7.2. Parenteral  

8. Global HIV Drugs Market, By Distribution Channel, 2019-2032 (USD Million)
8.1. Hospital Pharmacies
8.2. Online Pharmacies
8.3. Others 
8.4. Retail Pharmacies

9. Global HIV Drugs Market, By Region, 2019-2032 (USD Million)
9.1 North America
9.1.1 United States
9.1.2 Canada
9.1.3 Mexico
9.2 Europe
9.2.1 Germany
9.2.2 United Kingdom
9.2.3 France
9.2.4 Italy
9.2.5 Spain
9.2.6 Rest of Europe
9.3 Asia-Pacific
9.3.1 China
9.3.2 Japan
9.3.3 India
9.3.4 Australia
9.3.5 South Korea
9.3.6 Rest of Asia-Pacific
9.4 South America
9.4.1 Brazil
9.4.2 Argentina
9.4.3 Rest of South America
9.5 Middle East & Africa
9.5.1 Kingdom of Saudi Arabia 
9.5.2 United Arab Emirates
9.5.3 Rest of Middle East & Africa

10. Company Profiles
10.1 Abbvie Inc.
10.1.1 Company details 
10.1.2 Financial outlook
10.1.3 Product summary 
10.1.4 Recent developments

10.2 Aelix Therapeutics
10.2.1 Company details 
10.2.2 Financial outlook
10.2.3 Product summary 
10.2.4 Recent developments

10.3 AIM ImmunoTech
10.3.1 Company details 
10.3.2 Financial outlook
10.3.3 Product summary 
10.3.4 Recent developments

10.4 BioNTech
10.4.1 Company details 
10.4.2 Financial outlook
10.4.3 Product summary 
10.4.4 Recent developments

10.5 Biosantech
10.5.1 Company details 
10.5.2 Financial outlook
10.5.3 Product summary 
10.5.4 Recent developments

10.6 Boehringer Ingelheim International GmbH
10.6.1 Company details 
10.6.2 Financial outlook
10.6.3 Product summary 
10.6.4 Recent developments

10.7 Bristrol-Myers Squibb Company
10.7.1 Company details 
10.7.2 Financial outlook
10.7.3 Product summary 
10.7.4 Recent developments

10.8 CytoDyn
10.8.1 Company details 
10.8.2 Financial outlook
10.8.3 Product summary 
10.8.4 Recent developments

10.9 Dewpoint Therapeutics
10.9.1 Company details 
10.9.2 Financial outlook
10.9.3 Product summary 
10.9.4 Recent developments

10.10 Gilead Sciences
10.10.1 Company details 
10.10.2 Financial outlook
10.10.3 Product summary 
10.10.4 Recent developments

10.11 GlaxoSmithKline
10.11.1 Company details 
10.11.2 Financial outlook
10.11.3 Product summary 
10.11.4 Recent developments

10.12 ImmunityBio
10.12.1 Company details 
10.12.2 Financial outlook
10.12.3 Product summary 
10.12.4 Recent developments

10.13 Janssen Pharmaceuticals
10.13.1 Company details 
10.13.2 Financial outlook
10.13.3 Product summary 
10.13.4 Recent developments

10.14 Japan Tobacco
10.14.1 Company details 
10.14.2 Financial outlook
10.14.3 Product summary 
10.14.4 Recent developments

10.15 Merck 
10.15.1 Company details 
10.15.2 Financial outlook
10.15.3 Product summary 
10.15.4 Recent developments

10.16 Mylan 
10.16.1 Company details 
10.16.2 Financial outlook
10.16.3 Product summary 
10.16.4 Recent developments

10.17 Roche
10.17.1 Company details 
10.17.2 Financial outlook
10.17.3 Product summary 
10.17.4 Recent developments

10.18 Shionogi 
10.18.1 Company details 
10.18.2 Financial outlook
10.18.3 Product summary 
10.18.4 Recent developments

10.19 Starpharma 
10.19.1 Company details 
10.19.2 Financial outlook
10.19.3 Product summary 
10.19.4 Recent developments

10.20 TaiMed Biologics
10.20.1 Company details 
10.20.2 Financial outlook
10.20.3 Product summary 
10.20.4 Recent developments

10.21 Theratechnologies 
10.21.1 Company details 
10.21.2 Financial outlook
10.21.3 Product summary 
10.21.4 Recent developments

10.22 ViiV Heathcare
10.22.1 Company details 
10.22.2 Financial outlook
10.22.3 Product summary 
10.22.4 Recent developments

SPER Market Research’s methodology uses great emphasis on primary research to ensure that the market intelligence insights are up to date, reliable and accurate. Primary interviews are done with players involved in each phase of a supply chain to analyze the market forecasting. The secondary research method is used to help you fully understand how the future markets and the spending patterns look likes.

The report is based on in-depth qualitative and quantitative analysis of the Product Market. The quantitative analysis involves the application of various projection and sampling techniques. The qualitative analysis involves primary interviews, surveys, and vendor briefings.  The data gathered as a result of these processes are validated through experts opinion. Our research methodology entails an ideal mixture of primary and secondary initiatives.

SPER-Methodology-1

SPER-Methodology-2

SPER-Methodology-3


Frequently Asked Questions About This Report
The key players in the market include Companies Covered Abbvie Inc., Aelix Therapeutics, AIM ImmunoTech, BioNTech, Biosantech, Boehringer Ingelheim International GmbH, Bristrol-Myers Squibb Company, CytoDyn, Dewpoint Therapeutics, Gilead Sciences, GlaxoSmithKline, ImmunityBio, Janssen Pharmaceuticals, Japan Tobacco, Merck, Mylan, Roche, Shionogi, Starpharma, TaiMed Biologics, Theratechnologies, ViiV Healthcare.
The HIV Drugs Market is projected to reach USD 49.74 million by 2032, growing at a CAGR of 4.05% during the forecast period.
The HIV Drugs Market grew in market size from 2021. The Market is expected to reach USD 49.74 million by 2032, at a CAGR of 4.05% during the forecast period.
The HIV Drugs Market CAGR of 4.05% during the forecast period.
You can get the sample pages by clicking the link - Click Here
The HIV Drugs Market size is USD 49.74 million from 2022 to 2032.
The HIV Drugs Market segment is Covered By Drug Class, By Administration, By Distribution Channel.
The North America and Europe region is anticipated to have the highest market share in the HIV Drugs Market.
One of the primary factors driving the global market for HIV drugs is the rise in HIV prevalence and diagnosis.
Not able to find what you are looking for? Need customization in the existing report?
Click Here
PLACE AN ORDER
  • 15% off
     
    $ 4250
  • 20% off
             
    $ 5650
  • 25% off
         
    $ 7450
Pre-Purchase Inquiry
SEND AN INQUIRY
NEED CUSTOMIZATION?
Request Customization
CALL OR EMAIL US
US:
India:
Email:
100% Secure Payment

SPER American Express
SPER VISA
SPER Master Card
SPER Mestro
SPER Paypal
SPER CCAvenues

Join Our SPER Panel

Our Global Clients

Our data-driven insights have influenced the strategy of 200+ reputed companies across the globe.
SPER-Astellas Pharma
SPER-Citi Bank
SPER-Microsoft
SPER-EY
SPER-Sanofi
SPER-p&g
SPER-Johnson & Johnson
SPER-SIEMENS
SPER-LOREAL
SPER-Pfizer
SPER-IPSOS
SPER-Heineken
SPER-IQVIA
SPER-Kankar IMRB
SPER-Astellas Pharma
SPER-Citi Bank
SPER-Microsoft
SPER-EY
SPER-Sanofi
SPER-p&g
SPER-Johnson & Johnson
SPER-SIEMENS
SPER-LOREAL
SPER-Pfizer
SPER-IPSOS
SPER-Heineken
SPER-IQVIA
SPER-Kankar IMRB

SPER

Market Research

We are the leading, full-service global market research and consulting company.

Certificates
iso-1 iso-1
Secure Payments
SPER Payment Options
Connect with us